Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Understanding pain in depression.

Stephen Stahl1, Mike Briley

  • 1Neuroscience Education Institute, Carlsbad, CA 92009, USA. smstahl@neiglobal.com

Human Psychopharmacology
|September 21, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.

Therapeutic advances in psychopharmacology·2025
Same author

Ritual to relief: ethical frontiers in repurposing psychoactive substances.

CNS spectrums·2025
Same author

MAOI Antidepressants: A History Being Rewritten.

The Journal of clinical psychiatry·2025
Same author

Toward Precision Psychiatry: Innovations and Prospects in Treating Depression.

The primary care companion for CNS disorders·2025
Same author

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.

The Journal of clinical psychiatry·2025
Same author

Reply to Letter From Surekha et al: "Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions".

Journal of clinical psychopharmacology·2025
Same journal

Evaluation of Oculomotor Function Following Sleep Improvement With Lemborexant in Older Adults With Insomnia.

Human psychopharmacology·2026
Same journal

Relationship Between Clozapine Levels and Adverse Effects Evaluated by the GASS-C in Treatment-Resistant Schizophrenia.

Human psychopharmacology·2026
Same journal

ADHD, Psychotropic Medication and Pregnancy: The Influence of Maternal ADHD on Child Development-A Retrospective Cohort Study.

Human psychopharmacology·2026
Same journal

Long-Term Trends in Prescribing of Etizolam for Hypnotic Use in a Japanese University Hospital.

Human psychopharmacology·2026
Same journal

Verbal and Visuospatial Working Memory Performance During the CO<sub>2</sub> Challenge Model of Anxiety.

Human psychopharmacology·2026
Same journal

Serum Galectin-1 and Galectin-3 Levels and Their Relationship With Executive Functions and Memory in Patients With Major Depressive Disorder.

Human psychopharmacology·2026
See all related articles

Dysfunction in serotonin and norepinephrine pathways contributes to depression. These neurotransmitter systems impact mood, cognition, and even physical pain perception.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Neurobiology

Background:

  • Depression is linked to dysfunctions in serotonergic and noradrenergic pathways.
  • These pathways involve neurotransmitters serotonin and norepinephrine, crucial for mood, cognition, and behavior.
  • Neurons in the raphe nucleus (serotonergic) and locus coeruleus (noradrenergic) project throughout the brain and spinal cord.

Purpose of the Study:

  • To elucidate the role of serotonergic and noradrenergic pathways in the etiology of depression.
  • To explain how dysfunctions in these ascending and descending pathways contribute to both psychological and somatic symptoms of depression.

Main Methods:

  • Review of established neurobiological pathways.
  • Analysis of the functional roles of serotonergic and noradrenergic neurons in the central nervous system.

Related Experiment Videos

  • Examination of the impact of pathway dysfunction on mood, cognition, and sensory processing.

    • Main Results:

    • Dysfunction in monoamine neurons leads to classical depression symptoms via ascending pathways affecting mood, emotion, and behavior.
    • Descending pathways from the raphe nucleus and locus ceruleus normally inhibit sensory input, a function amplified during stress.
    • Impaired serotonergic and noradrenergic signaling affects both ascending and descending pathways, causing psychological, somatic, and physical pain symptoms.

    Conclusions:

    • Serotonergic and noradrenergic pathway dysfunction is central to depression's diverse symptoms.
    • Both ascending (mood, cognition) and descending (sensory inhibition) pathways are implicated.
    • Understanding these pathways offers insights into the complex presentation of depression, including physical pain.